Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael H Davidson

Showing results (1-10 of 300) with videos related to

Pageof 30
Sort By:
Expert Opinion on Drug Safety|August 9, 2003
Controversy surrounding the safety of cerivastatinMichael H Davidson
Current Atherosclerosis Reports|August 13, 2003
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary eventsMichael H Davidson
Journal of the American College of Cardiology|January 25, 2011
Apolipoprotein A-I therapy promise, challenges, and disappointmentMichael H Davidson
Drugs & Aging|October 24, 2007
Rosuvastatin in elderly patientsMichael H Davidson
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?Michael H Davidson
The American Journal of Managed Care|January 12, 2008
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directorsMichael H Davidson
The American Journal of Cardiology|March 20, 2002
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. IntroductionMichael H Davidson
Cardiovascular Drugs and Therapy|October 22, 2009
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et alMichael H Davidson
The American Journal of Cardiology|November 18, 2005
Reducing residual risk for patients on statin therapy: the potential role of combination therapyMichael H Davidson
European Heart Journal|January 18, 2018
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-CMichael H Davidson
Pageof 30

Showing results (1-10 of 300) with videos related to

Sort By:
Pageof 30
Expert Opinion on Drug Safety|August 9, 2003
Controversy surrounding the safety of cerivastatinMichael H Davidson
Current Atherosclerosis Reports|August 13, 2003
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary eventsMichael H Davidson
Journal of the American College of Cardiology|January 25, 2011
Apolipoprotein A-I therapy promise, challenges, and disappointmentMichael H Davidson
Drugs & Aging|October 24, 2007
Rosuvastatin in elderly patientsMichael H Davidson
Nature Clinical Practice. Cardiovascular Medicine|October 26, 2006
Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?Michael H Davidson
The American Journal of Managed Care|January 12, 2008
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directorsMichael H Davidson
The American Journal of Cardiology|March 20, 2002
A symposium: National Cholesterol Education Program Adult Treatment Panel III: Impact and implementation of the new guidelines. IntroductionMichael H Davidson
Cardiovascular Drugs and Therapy|October 22, 2009
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et alMichael H Davidson
The American Journal of Cardiology|November 18, 2005
Reducing residual risk for patients on statin therapy: the potential role of combination therapyMichael H Davidson
European Heart Journal|January 18, 2018
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-CMichael H Davidson
Pageof 30